FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1484-1491 May 18, 2000 Number 20 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.

Methods In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2–receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive supplementary levodopa, administered in an open-label fashion. The primary outcome measure was the occurrence of dyskinesia.

Results Eighty-five of the 179 patients in the ropinirole group (47 percent) and 45 of the 89 patients in the levodopa group (51 percent) completed all five years of the study. In the ropinirole group, 29 of the 85 patients (34 percent) received no levodopa supplementation. The analysis of the time to dyskinesia showed a significant difference in favor of ropinirole (hazard ratio for remaining free of dyskinesia, 2.82; 95 percent confidence interval, 1.78 to 4.44; P<0.001). At five years, the cumulative incidence of dyskinesia (excluding the three patients who had dyskinesia at base line), regardless of levodopa supplementation, was 20 percent (36 of 177 patients) in the ropinirole group and 45 percent (40 of 88 patients) in the levodopa group. There was no significant difference between the two groups in the mean change in scores for activities of daily living among those who completed the study. Adverse events led to the early withdrawal from the study of 48 of 179 patients in the ropinirole group (27 percent) and 29 of 89 patients in the levodopa group (33 percent). The mean (±SD) daily doses given by the end of the study were 16.5±6.6 mg of ropinirole (plus 427±221 mg of levodopa in patients who received supplementation) and 753±398 mg of levodopa (including supplements).

Conclusions Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.

Source Information

From the Clinical Investigation Center, Neuropharmacology Unit, INSERM Unité 455, University Hospital, Toulouse, France (O.R.); the Division of Neuroscience, Imperial College School of Medicine, Hammersmith Hospital, London (D.J.B.); the Department of Neurology, Tel Aviv University Medical School, Ramat Aviv, Israel (A.D.K.); the Department of Neurology, General Hospital Middelheim, Born-Bunge Foundation, and University of Antwerp, Antwerp, Belgium (P.P.D.); the Department of Neurology, University of Birmingham, Birmingham, United Kingdom (C.E.C.); and the Department of Medicine (Neurology), University of Toronto and Toronto Western Hospital, Toronto (A.E.L.). Presented at the XIII International Congress on Parkinson's Disease, Vancouver, Canada, July 24–28, 1999.

Address reprint requests to Dr. Rascol at the Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, 37 Allées Jules-Guesde, 31073 Toulouse CEDEX, France, or at rascol{at}cict.fr.

Full Text of this Article

Related Letters:

Ropinirole as Compared with Levodopa in Parkinson's Disease
Hiner B. C., Earnhart M., Yamamoto T., Frucht S., Weiner W. J., Factor S. A., Rascol O., The 056 Study Group
Extract | Full Text  
N Engl J Med 2000; 343:884-885, Sep 21, 2000. Correspondence

This article has been cited by other articles:

• Uc, E. Y., McDermott, M. P., Marder, K. S., Anderson, S. W., Litvan, I., Como, P. G., Auinger, P., Chou, K. L., Growdon, J. C., On behalf of the Parkinson Study Group DATATOP Inv, (2009). Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73: 1469-1477 [Abstract] [Full Text]  
• Isaacson, S. H., Hauser, R. A. (2009). Review: Improving symptom control in early Parkinson's disease. Therapeutic Advances in Neurological Disorders 2: 393-400 [Abstract]  
• Groiss, S.J., Wojtecki, L., Sudmeyer, M., Schnitzler, A. (2009). Review: Deep brain stimulation in Parkinson's disease. Therapeutic Advances in Neurological Disorders 2: 379-391 [Abstract]  
• Cawello, W., Braun, M., Boekens, H. (2009). Absorption, Disposition, Metabolic Fate, and Elimination of the Dopamine Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery. Drug Metab. Dispos. 37: 2055-2060 [Abstract] [Full Text]  
• Stoner, S. C, Dahmen, M. M, Makos, M., Lea, J. W, Carver, L. J, Rasu, R. S (2009). An Exploratory Retrospective Evaluation of Ropinirole-Associated Psychotic Symptoms in an Outpatient Population Treated for Restless Legs Syndrome or Parkinson's Disease. The Annals of Pharmacotherapy 43: 1426-1432 [Abstract] [Full Text]  
• Koch, G., Brusa, L., Carrillo, F., Lo Gerfo, E., Torriero, S., Oliveri, M., Mir, P., Caltagirone, C., Stanzione, P. (2009). Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. Neurology 73: 113-119 [Abstract] [Full Text]  
• Addy, C., Assaid, C., Hreniuk, D., Stroh, M., Xu, Y., Herring, W. J., Ellenbogen, A., Jinnah, H. A., Kirby, L., Leibowitz, M. T., Stewart, R. M., Tarsy, D., Tetrud, J., Stoch, S. A., Gottesdiener, K., Wagner, J. (2009). Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease. J Clin Pharmacol 49: 856-864 [Abstract] [Full Text]  
• Montgomery, E. B. Jr, Weiner, W. J., Reich, S. G. (2009). AGONIST OR LEVODOPA FOR PARKINSON DISEASE? ULTIMATELY, IT DOESN'T MATTER; NEITHER IS GOOD ENOUGH. Neurology 72: 2137-2138 [Full Text]  
• Olanow, C. W., Stern, M. B., Sethi, K. (2009). The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-S136 [Abstract] [Full Text]  
• Parkinson Study Group CALM Cohort Investigators, (2009). Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease. Arch Neurol 66: 563-570 [Abstract] [Full Text]  
• Bostwick, J. M., Hecksel, K. A., Stevens, S. R., Bower, J. H., Ahlskog, J. E. (2009). Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease. Mayo Clin Proc. 84: 310-316 [Abstract] [Full Text]  
• Pisani, A., Shen, J. (2009). Levodopa-induced dyskinesia and striatal signaling pathways. Proc. Natl. Acad. Sci. USA 106: 2973-2974 [Full Text]  
• Sujith, O.K., Lane, C. (2009). Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease. Therapeutic Advances in Neurological Disorders 2: 105-113 [Abstract]  
• Lang, A. E. (2009). When and how should treatment be started in Parkinson disease?. Neurology 72: S39-S43 [Abstract] [Full Text]  
• Rascol, O. (2009). "Disease-modification" trials in Parkinson disease: Target populations, endpoints and study design. Neurology 72: S51-S58 [Abstract] [Full Text]  
• Foltynie, T, Cheeran, B, Williams-Gray, C H, Edwards, M J, Schneider, S A, Weinberger, D, Rothwell, J C, Barker, R A, Bhatia, K P (2009). BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 80: 141-144 [Abstract] [Full Text]  
• LeWitt, P. A. (2008). Levodopa for the Treatment of Parkinson's Disease. NEJM 359: 2468-2476 [Full Text]  
• Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Bjorklund, A., Bezard, E., Carta, M. (2008). Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131: 3380-3394 [Abstract] [Full Text]  
• Weiner, W. J., Reich, S. G. (2008). Agonist or levodopa for Parkinson disease?: Ultimately, it doesn't matter; neither is good enough. Neurology 71: 470-471 [Full Text]  
• Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., Lees, A. J., On behalf of the Parkinson's Disease Research Grou, (2008). Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71: 474-480 [Abstract] [Full Text]  
• Chen, J. J., Pahwa, R. (2008). Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease. Journal of Pharmacy Practice 21: 244-253 [Abstract]  
• Waters, C. H., Chen, J. J. (2008). Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off''. Journal of Pharmacy Practice 21: 254-261 [Abstract]  
• Davie, C. A. (2008). A review of Parkinson's disease. Br Med Bull 86: 109-127 [Abstract] [Full Text]  
• Marras, C., Lang, A. (2008). Invited Article: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain. Neurology 70: 1996-2003 [Abstract] [Full Text]  
• Chen, L., Ding, Y., Cagniard, B., Van Laar, A. D., Mortimer, A., Chi, W., Hastings, T. G., Kang, U. J., Zhuang, X. (2008). Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice. J. Neurosci. 28: 425-433 [Abstract] [Full Text]  
• Gold, S. J., Hoang, C. V., Potts, B. W., Porras, G., Pioli, E., Kim, K. W., Nadjar, A., Qin, C., LaHoste, G. J., Li, Q., Bioulac, B. H., Waugh, J. L., Gurevich, E., Neve, R. L., Bezard, E. (2007). RGS9 2 Negatively Modulates L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease. J. Neurosci. 27: 14338-14348 [Abstract] [Full Text]  
• Simonson, W., Hauser, R. A, Schapira, A. H. (2007). Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease. The Annals of Pharmacotherapy 41: 1842-1849 [Abstract] [Full Text]  
• Schapira, A. H. V. (2007). Treatment Options in the Modern Management of Parkinson Disease. Arch Neurol 64: 1083-1088 [Full Text]  
• Thanvi, B., Lo, N., Robinson, T. (2007). Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad. Med. J. 83: 384-388 [Abstract] [Full Text]  
• Jankovic, J., Watts, R. L., Martin, W., Boroojerdi, B., for the SP 512 Rotigotine Transdermal System Clini, (2007). Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease. Arch Neurol 64: 676-682 [Abstract] [Full Text]  
• Chou, K. L., Stacy, M. A. (2007). Skin rash associated with Sinemet does not equal levodopa allergy. Neurology 68: 1078-1079 [Full Text]  
• Splinter, M. Y (2007). Rotigotine: Transdermal Dopamine Agonist Treatment of Parkinson's Disease and Restless Legs Syndrome. The Annals of Pharmacotherapy 41: 285-295 [Abstract] [Full Text]  
• Watts, R. L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B., Rao, J. (2007). Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68: 272-276 [Abstract] [Full Text]  
• Linazasoro, G. (2007). Pathophysiology of Motor Complications in Parkinson Disease: Postsynaptic Mechanisms Are Crucial. Arch Neurol 64: 137-140 [Full Text]  
• Hauser, R. A., McDermott, M. P., Messing, S., for the Parkinson Study Group, (2006). Factors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson Disease. Arch Neurol 63: 1756-1760 [Abstract] [Full Text]  
• Morris, M. E (2006). Locomotor Training in People With Parkinson Disease. ptjournal 86: 1426-1435 [Abstract] [Full Text]  
• Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schafer, H., Botzel, K., Daniels, C., Deutschlander, A., Dillmann, U., Eisner, W., Gruber, D., Hamel, W., Herzog, J., Hilker, R., Klebe, S., Kloss, M., Koy, J., Krause, M., Kupsch, A., Lorenz, D., Lorenzl, S., Mehdorn, H. M., Moringlane, J. R., Oertel, W., Pinsker, M. O., Reichmann, H., Reuss, A., Schneider, G.-H., Schnitzler, A., Steude, U., Sturm, V., Timmermann, L., Tronnier, V., Trottenberg, T., Wojtecki, L., Wolf, E., Poewe, W., Voges, J., the German Parkinson Study Group, Neurostimulation, (2006). A randomized trial of deep-brain stimulation for Parkinson's disease.. NEJM 355: 896-908 [Abstract] [Full Text]  
• Swarztrauber, K., Koudelka, C., Brodsky, M. A. (2006). Initial pharmacotherapy in a population of veterans with Parkinson disease. Neurology 66: 1425-1426 [Abstract] [Full Text]  
• Palhagen, S., Heinonen, E., Hagglund, J., Kaugesaar, T., Maki-Ikola, O., Palm, R., the Swedish Parkinson Study Group, (2006). Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66: 1200-1206 [Abstract] [Full Text]  
• Samuel, M., Maidment, I., Boustani, M., Fox, C. (2006). Clinical management of Parkinson's disease dementia: pitfalls and progress. Adv. Psychiatr. Treat. 12: 121-129 [Abstract] [Full Text]  
• Van Gerpen, J. A., Kumar, N., Bower, J. H., Weigand, S., Ahlskog, J. E. (2006). Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 63: 205-209 [Abstract] [Full Text]  
• Parkinson Study Group, (2006). A Randomized Controlled Trial of Etilevodopa in Patients With Parkinson Disease Who Have Motor Fluctuations. Arch Neurol 63: 210-216 [Abstract] [Full Text]  
• Guimaraes, P., Kieburtz, K., Goetz, C. G, Elm, J. J, Palesch, Y. Y, Huang, P., Ravina, B., Tanner, C. M, Tilley, B. C (2005). Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials 2: 509-518 [Abstract]  
• Schapira, A H V (2005). Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76: 1472-1478 [Abstract] [Full Text]  
• Nutt, J. G., Wooten, G. F. (2005). Diagnosis and Initial Management of Parkinson's Disease. NEJM 353: 1021-1027 [Full Text]  
• Kuan, W. -L., Barker, R. A. (2005). New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants. Neurorehabil Neural Repair 19: 155-181 [Abstract]  
• Stephenson, D. T., Meglasson, M. D., Connell, M. A., Childs, M. A., Hajos-Korcsok, E., Emborg, M. E. (2005). The Effects of a Selective Dopamine D2 Receptor Agonist on Behavioral and Pathological Outcome in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Squirrel Monkeys. J. Pharmacol. Exp. Ther. 314: 1257-1266 [Abstract] [Full Text]  
• Koch, G., Brusa, L., Caltagirone, C., Peppe, A., Oliveri, M., Stanzione, P., Centonze, D. (2005). rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology 65: 623-625 [Abstract] [Full Text]  
• Avorn, J., Schneeweiss, S., Sudarsky, L. R., Benner, J., Kiyota, Y., Levin, R., Glynn, R. J. (2005). Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease. Arch Neurol 62: 1242-1248 [Abstract] [Full Text]  
• Jenner, P. (2005). A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65: S3-S5 [Abstract] [Full Text]  
• Poewe, W., Luessi, F. (2005). Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 65: S11-S14 [Full Text]  
• Adler, C. H., Thorpy, M. J. (2005). Sleep issues in Parkinson's disease. Neurology 64: S12-S20 [Abstract] [Full Text]  
• Stocchi, F., Vacca, L., Ruggieri, S., Olanow, C. W. (2005). Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease: A Clinical and Pharmacokinetic Study. Arch Neurol 62: 905-910 [Abstract] [Full Text]  
• Kurlan, R. (2005). "Levodopa phobia": A new iatrogenic cause of disability in Parkinson disease. Neurology 64: 923-924 [Full Text]  
• Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., Gwinn-Hardy, K., McFarland, H., Innis, R., Katz, R. G., Kieburtz, K., Kish, S. J., Lange, N., Langston, J. W., Marek, K., Morin, L., Moy, C., Murphy, D., Oertel, W. H., Oliver, G., Palesch, Y., Powers, W., Seibyl, J., Sethi, K. D., Shults, C. W., Sheehy, P., Stoessl, A. J., Holloway, R. (2005). The role of radiotracer imaging in Parkinson disease. Neurology 64: 208-215 [Abstract] [Full Text]  
• Weiner, W. J. (2004). Initial Treatment of Parkinson Disease: Levodopa or Dopamine Agonists. Arch Neurol 61: 1966-1969 [Full Text]  
• Stern, M. B. (2004). Dopamine Agonists Modify the Course of Parkinson Disease. Arch Neurol 61: 1969-1971 [Full Text]  
• de la Fuente-Fernandez, R., Sossi, V., Huang, Z., Furtado, S., Lu, J.-Q., Calne, D. B., Ruth, T. J., Stoessl, A. J. (2004). Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127: 2747-2754 [Abstract] [Full Text]  
• Horn, S., Stern, M. B. (2004). The comparative effects of medical therapies for Parkinson's disease. Neurology 63: S7-S12 [Full Text]  
• Noyes, K., Dick, A. W., Holloway, R. G., Parkinson Study Group, (2004). Pramipexole v. Levodopa as Initial Treatment for Parkinson's Disease: A Randomized Clinical-Economic Trial. Med Decis Making 24: 472-485 [Abstract]  
• Olanow, C. W., Kieburtz, K., Stern, M., Watts, R., Langston, J. W., Guarnieri, M., Hubble, J., for the US01 Study Team, (2004). Double-blind, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Stable Parkinson Disease. Arch Neurol 61: 1563-1568 [Abstract] [Full Text]  
• Burn, D. J., Troster, A. I. (2004). Neuropsychiatric Complications of Medical and Surgical Therapies for Parkinson's Disease. J Geriatr Psychiatry Neurol 17: 172-180 [Abstract]  
• Stocchi, F., Arnold, G., Onofrj, M., Kwiecinski, H., Szczudlik, A., Thomas, A., Bonuccelli, U., Van Dijk, A., Cattaneo, C., Sala, P., Fariello, R. G. (2004). Improvement of motor function in early Parkinson disease by safinamide. Neurology 63: 746-748 [Abstract] [Full Text]  
• Corvol, J.-C., Muriel, M.-P., Valjent, E., Feger, J., Hanoun, N., Girault, J.-A., Hirsch, E. C., Herve, D. (2004). Persistent Increase in Olfactory Type G-Protein {alpha} Subunit Levels May Underlie D1 Receptor Functional Hypersensitivity in Parkinson Disease. J. Neurosci. 24: 7007-7014 [Abstract] [Full Text]  
• Thanvi, B R, Lo, T C N (2004). Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 80: 452-458 [Abstract] [Full Text]  
• The Parkinson Study Group, (2004). Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial. Arch Neurol 61: 1044-1053 [Abstract] [Full Text]  
• Calon, F., Dridi, M., Hornykiewicz, O., Bedard, P. J., Rajput, A. H., Di Paolo, T. (2004). Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127: 1075-1084 [Abstract] [Full Text]  
• Ismail, M. S., Richard, I. H. (2004). A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease?. J. Neuropsychiatry Clin. Neurosi. 16: 8-18 [Abstract] [Full Text]  
• Montgomery, E. B., Pan, T., Le, W., Jankovic, J., Ahlskog, J. E., Wooten, G. F., Albin, R. L., Frey, K. A. (2004). Slowing Parkinson's disease progression: Recent dopamine agonist trials. Neurology 62: 343-345 [Full Text]  
• Schapira, A. H. V., Olanow, C. W. (2004). Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions. JAMA 291: 358-364 [Abstract] [Full Text]  
• Koller, W. C., Tse, W. (2004). Unmet medical needs in Parkinson's disease. Neurology 62: S1-8 [Abstract] [Full Text]  
• LeWitt, P. A., Nyholm, D. (2004). New developments in levodopa therapy. Neurology 62: S9-16 [Abstract] [Full Text]  
• Poewe, W. (2004). The role of COMT inhibition in the treatment of Parkinson's disease. Neurology 62: S31-38 [Abstract] [Full Text]  
• Jenner, P. (2004). Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation. Neurology 62: S47-55 [Abstract] [Full Text]  
• Stocchi, F., Olanow, C. W. (2004). Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 62: S56-63 [Abstract] [Full Text]  
• Olanow, C. W., Stocchi, F. (2004). COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?. Neurology 62: S72-81 [Abstract] [Full Text]  
• Razmy, A., Lang, A. E., Shapiro, C. M. (2004). Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. Arch Neurol 61: 97-102 [Abstract] [Full Text]  
• Standaert, D. G. (2003). Introduction: Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease. Neurology 61: S30-31 [Full Text]  
• Shults, C. W. (2003). Treatments of Parkinson Disease: Circa 2003. Arch Neurol 60: 1680-1684 [Abstract] [Full Text]  
• The Parkinson Study Group, (2003). A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease. Arch Neurol 60: 1721-1728 [Abstract] [Full Text]  
• Montgomery, E. B. Jr., Wooten, G. F., Ahlskog, J. E., Albin, R. L., Frey, K. A. (2003). Agonists versus levodopa in PD: The thrilla of whitha. Neurology 61: 1462-1463 [Full Text]  
• Bonuccelli, U., Lucetti, C., Del Dotto, P., Ceravolo, R., Gambaccini, G., Bernardini, S., Rossi, G., Piaggesi, A. (2003). Orthostatic Hypotension in De Novo Parkinson Disease. Arch Neurol 60: 1400-1404 [Abstract] [Full Text]  
• Jenner, P. (2003). The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complications. Neurology 61: S4-11 [Abstract] [Full Text]  
• Barone, P. (2003). Clinical strategies to prevent and delay motor complications. Neurology 61: S12-16 [Abstract] [Full Text]  
• Schapira, A.H. V. (2003). Neuroprotection in PD--A role for dopamine agonists?. Neurology 61: S34-42 [Full Text]  
• Marek, K., Jennings, D., Seibyl, J. (2003). Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa. Neurology 61: S43-48 [Full Text]  
• Schapira, A.H. V. (2003). Disease-modifying strategies and challenges in PD: Interactive breakout sessions. Neurology 61: S56-63 [Full Text]  
• Laghi, F., Tobin, M. J. (2003). Disorders of the Respiratory Muscles. Am. J. Respir. Crit. Care Med. 168: 10-48 [Abstract] [Full Text]  
• Siderowf, A., Stern, M. (2003). Update on Parkinson Disease. ANN INTERN MED 138: 651-658 [Abstract] [Full Text]  
• Wooten, G.F. (2003). Agonists vs levodopa in PD: The thrilla of whitha. Neurology 60: 360-362 [Full Text]  
• Ahlskog, J. E. (2003). Slowing Parkinson's disease progression: Recent dopamine agonist trials. Neurology 60: 381-389 [Abstract] [Full Text]  
• Albin, R. L., Frey, K. A. (2003). Initial agonist treatment of Parkinson disease: A critique. Neurology 60: 390-394 [Abstract] [Full Text]  
• Guttman, M., Kish, S. J., Furukawa, Y. (2003). Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 168: 293-301 [Abstract] [Full Text]  
• Marras, C, Lang, A E (2003). Measuring motor complications in clinical trials for early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74: 143-146 [Full Text]  
• Lees, A J (2002). Drugs for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 73: 607-610 [Full Text]  
• Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., Jenner, P. (2002). Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates. J. Pharmacol. Exp. Ther. 303: 952-958 [Abstract] [Full Text]  
• Nicholson, G., Pereira, A. C., Hall, G. M. (2002). Parkinson's disease and anaesthesia. Br J Anaesth 89: 904-916 [Abstract] [Full Text]